57536
document
Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia . Endocrine disorders affect both the coagulation and fibrinolytic systems , and have been associated with the development of cardiovascular diseases . Thrombin-activatable fibrinolysis inhibitor ( TAFI ) is a link between coagulation and the fibrinolytic system . The aim of this study was to determine the effect of thyroid hormone excess and deficiency on TAFI levels and function . The effect of hyperthyroxinemia on TAFI was studied in healthy volunteers who were randomised to receive levothyroxine or no medication for 14 days in a crossover design . The effect of hypothyroidism on TAFI was studied in a multicentre observational cohort study . Blood was drawn before treatment of patients with newly diagnosed hypothyroidism and when euthyroidism was achieved . Plasma clot-lysis times , activated TAFI ( TAFIa ) -dependent prolongation of clot-lysis and TAFI levels were measured . Thyroid hormone excess resulted in a hypofibrinolytic condition and in an enhanced TAFIa-dependent prolongation of clot lysis . A trend towards decreased plasma TAFI levels was observed in healthy volunteers who used levothyroxine . Hypothyroidism resulted in hyperfibrinolysis and a reduced TAFIa-dependent prolongation of clot lysis . In conclusion , alterations of TAFIa-dependent prolongation of clot lysis in patients with thyroid disorders may cause an impaired haemostatic balance . The disturbed haemostatic balance in patients with hyperthyroidism might make them prone to thrombosis , while the risk for bleeding may increase in patients with hypothyroidism .
57537
Intervention_Physical
Thrombin-activatable fibrinolysis inhibitor
57538
Intervention_Physical
Thrombin-activatable fibrinolysis inhibitor ( TAFI )
57539
Intervention_Physical
TAFI
57540
Intervention_Pharmacological
TAFI
57541
Intervention_Pharmacological
levothyroxine
57542
Intervention_Control
no medication
57543
Intervention_Pharmacological
TAFI
57544
Intervention_Physical
TAFI ( TAFIa ) -dependent
57545
Intervention_Pharmacological
TAFI
57546
Intervention_Pharmacological
levothyroxine
57547
Intervention_Pharmacological
TAFIa-dependent
57548
Outcome_Physical
Plasma clot-lysis times
57549
Outcome_Physical
activated TAFI ( TAFIa ) -dependent prolongation of clot-lysis
57550
Outcome_Physical
TAFI levels
57551
Outcome_Physical
Thyroid hormone excess
57552
Outcome_Physical
hypofibrinolytic condition
57553
Outcome_Physical
TAFIa-dependent prolongation of clot lysis
57554
Outcome_Physical
decreased plasma TAFI levels
57555
Outcome_Physical
hyperfibrinolysis
57556
Outcome_Physical
TAFIa-dependent prolongation of clot lysis
57557
Outcome_Physical
TAFIa-dependent prolongation of clot lysis
57558
Outcome_Physical
haemostatic balance
57559
Outcome_Physical
disturbed haemostatic balance
57560
Outcome_Physical
bleeding
57561
Participant_Condition
hypothyroidism and hyperthyroxinaemia .
57562
Participant_Condition
healthy
57563
Participant_Condition
newly diagnosed hypothyroidism
57564
Participant_Condition
healthy
57565
Participant_Condition
patients with hyperthyroidism
57566
Participant_Condition
patients with hypothyroidism .